A log of the daily 13D / insider-buy digests sent to Telegram, newest first. Verbatim once the morning job logs them; reconstructed from the signals otherwise. 13FScore n/a = filer isn't in the scorecard yet (may still file a 13F — scored on demand for notable names).
Monday, November 16, 2026
📈 Alpha-Investor Signals — Mon 16 Nov 2026 filings
5 Schedule 13Ds scanned · 27 qualifying insider buys (1,284 Form 4s)
🔍 EMERGING (not on roster)
$BANL ·
CBL International (marine fuel logistics / bunkering, Asia-Pacific) — 41.5% [Med]
Chia Teck Lim (founder, chairman & CEO) — filed SCHEDULE 13D
Why: The founder-CEO moved from a passive 13G (47.9% last year) to a 13D, which signals he may act on control, for example a take-private, restructuring or strategic deal. The lower percentage looks like dilution rather than selling. It is a micro-cap with thin liquidity.
$AQB ·
AquaBounty Technologies (former GM-salmon farmer, now winding down assets) — 10.7% [Med]
Univest Securities, LLC (small-cap broker-dealer / placement agent)
Why: A broker-dealer holding more than 10% usually comes from a financing or placement position, not a long-term activist thesis. Expect shares to be sold over time; this is not a fundamental catalyst.
$CKX ·
CKX Lands (Louisiana land & mineral-royalty company) — 10.3% [Med]
Jacobs Private Equity II, LLC (Brad Jacobs' vehicle; XPO/QXO roll-up builder)
Why: This is the 13D for Jacobs' ~$1B convertible-preferred and warrant deal announced 9 Nov. He gets majority control and becomes chairman/CEO, turning a tiny land company into a new acquisition platform, much like QXO. The stock already re-rated; the risks are dilution and execution ·
news
$FUN ·
Six Flags Entertainment (regional theme-park operator) — 7.2% [Med]
H Partners Management (concentrated activist; Rehan Jaffer sits on the FUN board) · 13FScore 5/100
Why: H Partners keeps adding as the stock falls; last week Jaffer personally bought $9.2M. It is a bet on a merger-synergy and cost turnaround, with board influence under the May cooperation agreement. Risks: high leverage, weak attendance, and a poor 13F clone track record. Book: 2 pos, top-10 100% (FUN 54.5%, AAP 45.5%).
$AZTR ·
Azitra (microbiome/skin biotech pivoting to cosmetics) — 5.2% [Med]
Young Pharmaceuticals, Inc. (skincare/dermatology products company)
Why: A strategic stake from a skincare company fits Azitra's 2026 pivot to cosmetic protein programs, and could lead to a commercial partnership. It is a nano-cap that has relied on repeated financings, so dilution risk is high.
💰 INSIDER BUYS $FPS ·
Forgent Power Solutions (electrical gear for data centers & grid): CEO Gary Niederpruem bought $334k (16k sh @ ~$21.59) + CFO Amy Ard $300k (14.6k sh @ ~$20.52) [CLUSTER of 2]. Why: Both top officers bought on 16 Nov after the stock roughly halved from its IPO-era highs (a CFO change hit sentiment). They are signalling that AI data-center power demand is intact; the risk is order timing and high expectations.
$EMO ·
ClearBridge Energy Midstream Opportunity Fund (closed-end midstream energy fund): Prudential Financial (10%+ owner) acquired 1.0M sh for $35.0M @ $35. Why: The $35 price is far below EMO's ~$51 market price, so this is most likely a privately placed preferred/leverage security rather than an open-market common buy. Treat it as fund financing, not a conviction signal.
$HUBS ·
HubSpot (CRM & marketing software): Brian Halligan (co-founder, just re-appointed CEO) bought $5.0M (23k sh @ ~$217). Why: The co-founder bought a day after retaking the CEO job on 12 Nov, reversing his 2026 10b5-1 selling. That is a strong "I'm all in" signal after a deep software drawdown; the risk is AI pressure on seat-based SaaS pricing ·
news
$TEAM ·
Atlassian (team collaboration software (Jira, Confluence)): Mike Cannon-Brookes (CEO/co-founder) bought another $2.0M (13.4k sh @ ~$149). Why: This is his second ~$2M tranche in a week, a repeat founder buy after the software selloff; the risk is seat-based pricing pressure.
$SONO ·
Sonos (premium wireless home audio): director Joseph Kennedy bought $1.9M (100k sh @ ~$18.23). Why: A large director buy after earnings backs the post-app-fiasco recovery; the risk is soft consumer hardware demand.
$KURA ·
Kura Oncology (precision oncology (menin inhibitor ziftomenib)): CEO Troy Wilson bought $1.5M (200k sh @ ~$7.42). Why: The CEO is buying around the commercial launch of its first approved drug in AML; the risks are launch uptake and cash burn.
$PAM ·
Pampa Energía (Argentine power & gas producer): VP Damián Mindlin bought $1.4M (22.7k ADS @ ~$63.92). Why: The controlling family is adding to the Argentine energy reform/Vaca Muerta story; the main risks are country and political risk.
$OIG ·
Orion180 Insurance Group (Florida/coastal homeowners insurer): CEO Kenneth Gregg (10%+ owner) bought $1.0M (96k sh @ ~$10.66). Why: The founder is buying a recently listed insurer near its lows; the risks are hurricane exposure and reinsurance costs.
$SKYD ·
Skydance Corp (media & entertainment holding): director Gerry Cardinale (RedBird) bought $1.0M (130k sh @ ~$7.54). Why: A sponsor-affiliated director buying signals support for the media roll-up story; it remains an integration and cord-cutting risk.
Friday, November 13, 2026
📈 Alpha-Investor Signals — Fri 13 Nov 2026 filings
2 Schedule 13Ds scanned · 16 qualifying insider buys (1,411 Form 4s)
🔍 EMERGING (not on roster)
$COUR ·
Coursera, Inc. (online learning & degree platform) — 5.1% [Med]
New Enterprise Associates 13 LP (venture capital firm, ~$25B AUM) — filed SCHEDULE 13D
Why: Not new buying — the filing says Coursera's own buyback shrank the share count, pushing NEA's legacy venture stake into 13D territory. Read it as a passive holder, not an activist catalyst; the risk is NEA eventually distributing or selling shares.
💰 INSIDER BUYS
$STWD ·
Starwood Property Trust (commercial mortgage REIT): Barry Sternlicht (CEO/Chairman) bought $14.7M (1.245M sh @ ~$11.59) + director Jonathan Pollack $2.0M [CLUSTER of 2]. Why: Founder writing a ~$15M personal cheque alongside a $108M Q3 company buyback is a strong signal that management sees the dividend and book value as safe at these prices; the risk is CRE credit losses.
$FUN ·
Six Flags Entertainment (regional theme-park operator): Rehan Jaffer (director; H Partners activist) bought $9.2M (825k sh @ ~$11.42). Why: The H Partners activist is averaging down hard: the stock has roughly halved since his June buys near $23.5. He's betting on a merger-integration and cost turnaround; the risk is heavy debt and weak attendance.
$PSEC ·
Prospect Capital (business development company (BDC) lender): John Barry (CEO, 10%+ owner) bought $6.1M (4.0M sh @ ~$1.51). Why: Barry routinely buys his own BDC, so this is less informative than it looks; deep discount to NAV, but dilution and credit quality are the long-running risks.
$BH ·
Biglari Holdings (holding co. (Steak n Shake, insurance, oil)): Sardar Biglari (Chairman/CEO) bought $5.5M (3,657 Class A sh @ ~$355). Why: The controlling shareholder keeps tightening his grip at a discount to the sum of parts; there's little minority catalyst because governance is entirely his call.
$AKAM ·
Akamai Technologies (CDN, security & cloud compute): Tom Leighton (CEO/co-founder) bought $2.6M (30k sh @ ~$85). Why: Leighton's fourth-plus open-market buy in two years, made right after earnings, backs the security/compute pivot story; the risk is the shrinking legacy delivery business.
$SJT ·
San Juan Basin Royalty Trust (natural-gas royalty trust): Eric Oliver (10%+ owner; SoftVest) bought $2.0M (455k sh @ ~$4.41). Why: An activist-style holder adding to a gas royalty trust ahead of winter is a gas-price and distribution-restart bet; the risk is that the trust's payouts swing with gas prices and costs.
$TEAM ·
Atlassian (team collaboration software (Jira, Confluence)): Mike Cannon-Brookes (CEO/co-founder) bought $2.0M (13.4k sh @ ~$148). Why: A rare open-market buy by the co-founder after a deep software selloff signals he thinks AI-disruption fears are overdone; the risk is seat-based pricing pressure.
$IOND ·
Ionic Digital (bitcoin miner / data centers): Michael Abbate (director) bought $1.3M (19.6k sh @ ~$65). Why: A director buying a newly listed miner is a vote for the HPC/AI-hosting optionality; it remains highly bitcoin-sensitive.
$UPST ·
Upstart Holdings (AI consumer-lending marketplace): Paul Gu (CEO) bought $1.0M (50k sh @ ~$20.57). Why: The new CEO buying after a steep drawdown signals confidence in loan volumes and funding; the risk is credit and funding-market stress.
$TXO ·
TXO Partners (oil & gas MLP): Bob Simpson (director, 10%+ owner) bought $945k. Why: Steady accumulation by the co-founder, which supports the distribution story.
$NXGL ·
NEXGEL (hydrogel medical/consumer products): Brian Kieser (interim CEO, 10%+ owner) bought $733k @ $5.50. Why: A micro-cap insider adding; thin liquidity.
$KGS ·
Kodiak Gas Services (natural-gas compression): director Alexander Darden bought $450k.
$WY ·
Weyerhaeuser (timberland REIT): director Richard Beckwitt bought $307k @ ~$20.44.
$INDI ·
indie Semiconductor (auto semis / ADAS chips): director David Aldrich bought $299k @ $2.30.
Also:
Audax Private Credit Fund (non-traded BDC) — sponsor Audax bought $14.5M of its own fund (capital deployment, not a market signal).
📊 Rest: +1 other 13D filing (INTERMARKET CORP/NY on Pyxus, 4.6%, low conviction).
Research only — not investment advice. Thursday, November 12, 2026
🏛 Alpha-Investor Signals — 12 Nov 2026 filings
6 Schedule 13Ds scanned · 0 roster · 98 Form 4 buy rows (35 distinct buys after dedupe) · 11 Nov EDGAR index not yet available (retry next run)
🔍 EMERGING (not on roster)
$INM ·
InMed Pharmaceuticals (small-cap biotech, migraine-prevention pipeline post-Mentari merger) — 19.99% [High]
Fairmount Funds Management (concentrated healthcare/biotech investor) · 13FScore 91/100
Why: Fairmount reportedly led a large private placement alongside InMed's 2026 merger and is now capped right at 19.99% — the classic Nasdaq 20% limit, so it likely holds more via warrants/pre-funded shares. A top-scoring biotech picker with a 12-stock, very concentrated book; catalyst is the INM-089 pre-IND FDA meeting slated for Q4 2026. Risk: microcap liquidity and dilution. ·
news. Book: 12 pos, top-10 97.6%.
$PYYX ·
Pyxus International (global leaf-tobacco merchant) — 15.7% [High]
Owl Creek Asset Management (event-driven / distressed-credit hedge fund) · 13FScore 68/100
Why: Owl Creek is one of the creditors in Pyxus's 5 Nov transaction support agreement — a debt exchange plus equity offering to cut leverage and push out maturities. This is a creditor-to-owner restructuring play, not a clean activist bet; upside if deleveraging re-rates the equity, risk is dilution and Pyxus's second recap in about six years. ·
news. Book: 33 pos, top-10 77.8%.
$CDLR ·
Cadeler (offshore-wind installation vessel owner) — 13.9% [Med]
Scorpio Services Holding (Scorpio Group shipping family holding co.)
Why: Long-standing strategic holder since the 2024 Eneti merger, which took ~12.8% after backing Cadeler's ~$203M March raise; the move to 13.9% is incremental support for the fleet build-out. Structural, not activist; risk is offshore-wind project delays. ·
news
$INTZ ·
Intrusion (cybersecurity / AI threat-intel software) — 8.9% [Med]
Tego Cyber (OTC cybersecurity company, seller of VigilAigent)
Why: Likely deal consideration — Intrusion bought Tego's VigilAigent MSSP business in June (≈$3.5M ARR), and Tego appears to hold the INTZ shares it received. Watch for lock-up expiry and selling rather than accumulation. ·
news $AGLT ·
Agility Robotics (humanoid warehouse robots, ex-Churchill XI SPAC) — 5.2% [Med]
Jonathan Hurst (co-founder & chief robot officer)
Why: Founder ownership disclosure after the SPAC closed on 4 Nov — structural, not a buy signal. The stock is a $2.5B bet on humanoids with under $2M of 2025 revenue; risk is post-SPAC redemptions/lock-up selling. ·
news
Exxaro Resources (South African coal & minerals miner, JSE-listed) — 5.0% [Med]
Standard Bank of South Africa (Africa's largest bank by assets)
Why: A bank crossing exactly 5% in a JSE miner is most likely custody, financing or hedging-related — structural, low signal for US investors.
💰 INSIDER BUYS
$MP ·
MP Materials (US rare-earth miner & magnet maker): Randall Weisenburger (director) bought $1.98M and COO Michael Rosenthal bought $1.18M [CLUSTER of 2]. Why: Two insiders buying together at ~$36–37 on 10–11 Nov — the day's only true cluster; supports the domestic rare-earth supply-chain story. Risk: NdPr price swings and a heavy capex ramp.
$TEAM ·
Atlassian (Jira/Confluence collaboration software): Mike Cannon-Brookes (co-founder/CEO, 10% owner) bought $2.0M. Why: Founder-CEO open-market buy at ~$152 after a long drawdown in SaaS names — a confidence signal, small relative to his stake.
$LILA ·
Liberty Latin America (Caribbean & Latin American cable/telecom): Alfonso de Angoitia (director) bought $5.06M. Why: Sizeable director buy across three days at ~$20.30 — conviction in the deleveraging and asset-sale story.
$OBIO ·
Orchestra BioMed (cardiology device & drug biotech): RTW Investments (10% owner) bought $6.0M. Why: Healthcare specialist RTW adding 1.2M shares at $5 — likely a financing participation; supportive ahead of pivotal data.
$OFIX ·
Orthofix Medical (spine & orthopedics devices): Juniper Investment Co. (10% owner) bought $5.1M. Why: A 10%+ holder keeps adding near $7 — accumulation that could lead to board pressure.
$CTEV ·
Claritev (healthcare cost-management data (ex-MultiPlan)): Ares Management (10% owner) bought $2.9M. Why: Ares adding to a post-restructuring position at ~$26 — creditor-turned-owner conviction.
$FIP ·
FTAI Infrastructure (rail, ports & energy infrastructure): CEO Kenneth Nicholson bought $1.53M. Why: CEO buying 400K shares at ~$3.83 — a meaningful personal bet on a beaten-down stock.
$HOS ·
Hornbeck Offshore (offshore supply vessels): CEO Todd Hornbeck bought $1.5M. Why: Founder-CEO buying around $5.48 — owner-operator conviction.
Keenova Therapeutics (specialty pharmaceuticals): GoldenTree Asset Management (10% owner) bought $13.7M. Why: Distressed-credit giant adding about 150K shares at $91 — a large holder doubling down; no US ticker resolved.
📊 Rest: +0 other 13D filings today; +25 other insider buys (incl. COHR director $997K, Saba in MXF $755K, Bloomin' Brands CEO $502K). NFRX $44.5M is sponsor seed capital into its own ETF — structural.
Research only — not investment advice. Tuesday, November 10, 2026
🏛 Alpha-Investor Signals — 10 Nov 2026 filings
4 Schedule 13Ds scanned · 0 roster · 36 Form 4 buy rows (18 distinct buys after dedupe)
🔍 EMERGING (not on roster)
$PMAX ·
Powell Max (Hong Kong financial printing & IR services) — 21.7% [Med]
Hyperscale Data (Ault-controlled AI data-center & bitcoin holding co.)
Why: Hyperscale (GPUS) has a habit of buying control-sized stakes in tiny listed shells; a 21.7% position in a microcap looks like a balance-sheet or reverse-merger play rather than a clean value bet. Risk: thin liquidity and a highly dilutive, cash-hungry filer.
$CMMB ·
Chemomab Therapeutics (anti-CCL24 antibody biotech, merging) — 10.4% [Med]
Scipher Medicine (AI precision-medicine company, merger partner)
Why: Deal-mechanics filing — Scipher and Chemomab agreed an all-stock merger in July (to trade as SCIP, Scipher holders ~68%), closing expected Q4 2026; the stake reflects voting/support arrangements, not open-market accumulation. Catalyst: shareholder vote and close; risk: post-merger selling and Phase 2 RA data. ·
news
$LRN ·
Stride (online K-12 & career education) — 5.3% [Med]
Fivespan Partners (concentrated activist fund, 6-stock book)
Why: Fivespan is now over 5% after its director (Dylan Haggart, seated under an October cooperation deal) kept buying through the sell-off — a board-level activist pushing capital return/strategy. Book: 6 pos, top-10 100%.
Hugoton Royalty Trust (natural-gas royalty trust, OTC) — 5.2% [Med]
John P. Wandel Jr. (individual investor)
Why: Individual crossing 5% in a tiny, often zero-distribution gas royalty trust — a speculative bet on gas prices/trust value; low signal unless an agenda follows.
💰 INSIDER BUYS (no true clusters today — the ETRA “cluster” is one joint OrbiMed filing)
$FUN ·
Six Flags Entertainment (theme-park operator): Rehan Jaffer (H Partners) (director) bought $14.9M. Why: H Partners' founder bought 1.45M shares at ~$10.32 — less than half the ~$23.5 he paid in June. Big conviction double-down from a board-level holder; risk: leverage and weak attendance trends.
$TXO ·
TXO Partners (oil & gas producer MLP): Bob R. Simpson (director/10% owner) bought $3.08M. Why: XTO co-founder adding to his own MLP — owner-operator conviction on the distribution and asset base.
$MXF ·
Mexico Fund (Mexican-equity closed-end fund): Saba Capital (10% owner) bought $3.0M (2 filings). Why: Saba's classic closed-end-fund discount arbitrage — it buys below NAV and pushes for tenders/liquidity; event-driven, not a Mexico call.
$PSEC ·
Prospect Capital (business-development company (BDC)): John F. Barry (CEO/chairman) bought $1.73M. Why: CEO keeps buying around $1.41 — a long-running pattern; support for the stock rather than a fresh signal. Risk: NAV erosion and dividend cuts.
$LBTY ·
Liberty Global (European cable & telecom): John C. Malone (10% owner) bought $1.46M. Why: Malone adding to a deeply discounted sum-of-the-parts story with asset sales and spin-offs as catalysts.
$MX ·
Magnachip Semiconductor (display & power semiconductors): Cristiano Amoruso (director) bought $1.37M. Why: Independent director (ex-Suniva CEO, Navitas board) buying ~568K shares at $2.46 during the turnaround under new CEO Chae Lee.
$PRTA ·
Prothena (neuro-degeneration antibody biotech): William P. Scully (10% owner) bought $1.19M. Why: Large holder adding near $8.50 — conviction ahead of partnered pipeline readouts.
$ETRA ·
Electra Therapeutics (clinical-stage biotech): OrbiMed Advisors / Carl Gordon (director/10% owner) bought $745K. Why: Lead healthcare VC adding on the open market — supportive, modest size.
$NFRX ·
Harrison Street Infrastructure Active ETF (active infrastructure ETF): Harrison Street Real Assets Fund (10% owner) bought $24.5M. Why: Sponsor seed capital into its own ETF — structural, not a stock-picking signal.
Also bought ($300K–$700K): $BSM Black Stone Minerals (CEO), $CRH CRH (director), $FLOC Flowco (director/officer), $NVT nVent (director), $STVN Stevanato (director), $BOLT Bolt Bio (Coastlands Capital, 10% owner).
📊 Rest: +0 other 13D filings today.
Research only — not investment advice. Monday, November 9, 2026
🏛 Alpha-Investor Signals — 9 Nov 2026 filings
6 Schedule 13Ds scanned · 0 roster · 51 Form 4 buy rows (≈25 distinct buys after dedupe)
🔍 EMERGING (not on roster)
$MERC ·
Mercer International (pulp, lumber & mass-timber producer) — stake n/a [Med]
Redwood Capital Management (distressed/credit hedge fund) · 13FScore 79/100
Why: Redwood appears to have moved from a passive 13G to an activist 13D on a levered, cyclically stressed pulp name — watch for balance-sheet or strategic-alternatives pressure. Risk: pulp-price downturn and refinancing.
$ASPE ·
Aspen Neuroscience (autologous stem-cell therapy for Parkinson's) — 12.9% [Med]
ARCH Venture Fund X (top-tier biotech venture fund)
Why: Routine post-IPO 13D from a lead VC (IPO priced 29 Oct at $15, low end). Shows ARCH holding through the listing; catalyst is Phase 3 progress. Risk: lock-up expiry and trial readouts. ·
news
$HIHO ·
Highway Holdings (Hong Kong/China OEM metal-parts maker) — 16.7% [Med]
David E. Lazar (microcap activist known for shell/board takeovers)
Why: Lazar typically takes board control of tiny, cash-rich microcaps and pushes reverse mergers or recapitalisations — an event-driven, high-risk setup.
$GMHS ·
Gamehaus Holdings (mobile-game publisher (de-SPAC)) — 31.5% [Med]
Xie Feng (co-founder / insider holder)
Why: Founder ownership filing rather than outside accumulation; low signal unless followed by buying.
$GAME ·
GameSquare Holdings (esports/gaming media with an ETH treasury) — 5.4% [Med]
Credenza, Inc. (unidentified holder)
Why: New 5%+ holder just over the threshold; worth watching for follow-on buying or a stated agenda.
$ENGS ·
Energys Group (HK energy-efficiency solutions provider) — 98.9% [Med]
Lau Michael Kwok Yan (controlling shareholder)
Why: Near-total control stake by the controlling holder — a control filing, not a tradable activist signal.
💰 INSIDER BUYS (no clusters today)
$NFRX ·
Harrison Street Infrastructure Active ETF (active infrastructure-equity ETF): Harrison Street Real Assets Fund LLC (10% owner) bought $45.2M. Why: Affiliated sponsor capital going into its own ETF — structural, not a stock-picking signal.
Keenova Therapeutics (specialty pharma (ex-Mallinckrodt/Endo)): GoldenTree Asset Management (10% owner) bought $26.4M. Why: ~$50B credit manager adding to a 20%+ post-restructuring stake; continued conviction that the combined company is undervalued. Risk: opioid-legacy liabilities and leverage.
$LRN ·
Stride (online K-12 & career education): Dylan Haggart (Fivespan) (director) bought $8.1M. Why: Activist-turned-director under an October cooperation deal keeps buying after the stock's sell-off; the board seat signals push for capital return/strategy.
$NATR ·
Nature's Sunshine Products (herbal supplements via direct selling): Prescott Group Capital (10% owner) bought $2.85M. Why: Long-time ~10% holder steadily adding — value-oriented conviction in a cheap small cap.
$ROK ·
Rockwell Automation (industrial automation): Blake Moret (CEO/director) bought $1.55M. Why: Rare open-market buy by the CEO of a large cap — a confidence signal on the industrial cycle.
$PAM ·
Pampa Energía (Argentine power & gas): Damián Mindlin (officer) bought $1.29M. Why: Controlling family adding — bet on Argentine energy reform and Vaca Muerta gas.
$VDTA ·
Vertical Data (data-infrastructure microcap): Hamble International (10% owner) bought $1.0M.
$NLY ·
Annaly Capital (mortgage REIT): Scott Wede (director) bought $940K.
$FLOC ·
Flowco Holdings (oilfield artificial-lift equipment): Joseph Edwards (director/officer) bought $798K.
Also bought ($250K–$650K): $DGICA Donegal (parent mutual), $ADTN ADTRAN (CEO), $CMCO Columbus McKinnon (CEO), $WCC Wesco, $ADM ADM, $LUMN Lumen (CEO), $GFS GlobalFoundries, $DKNG DraftKings, $TTMI TTM Tech, $UPBD Upbound (CEO), $TSM TSMC (ADR, director), $MTDR Matador (CEO).
📊 Rest: +0 other 13D filings today.
Research only — not investment advice. Friday, November 6, 2026
🏛 Alpha-Investor Signals — Fri 6 Nov 2026 filings
12 Schedule 13Ds scanned · 2 high-conviction · 10 qualifying insider buys (0 clusters)
🔍 EMERGING (high-conviction, not on roster)
$BBTX ·
Bambusa Therapeutics, Inc. (immunology biotech, Phase 1 bispecific for eczema) — 14.6% [High]
RA CAPITAL MANAGEMENT, L.P. (life-sciences crossover fund, ~$10B AUM) · 13FScore 37/100
Why: RA led the Series A and holds a board seat; this 13D locks in its post-IPO stake after the 29 Oct IPO at $16 (opened below issue). Catalyst is early Phase 1 data for BBT001 (IL-4Rα/IL-31); risk is a single early-stage asset and a going-concern note in the prospectus. ·
news
$ASPE ·
Aspen Neuroscience, Inc. (Parkinson’s cell-therapy biotech (autologous iPSC)) — 12.3% [High]
ORBIMED ADVISORS LLC (healthcare-dedicated investor, ~$17B AUM) · 13FScore 49/100
Why: Pre-IPO holder carrying its stake through the 30 Oct Nasdaq debut (priced at the $15 low end, trading below). Phase 3 start for sasineprocel is guided for H2 2027; near-term risk is a weak post-IPO tape and long cash runway needs. ·
news
$TGE ·
Generation Essentials Group (AMTD-group media & entertainment holdco) — 95.7% [Med]
AMTD Group Inc. (Hong Kong conglomerate parent, controlling holder)
Why: Control-parent filing, not an outside activist — effectively the parent's stake in its own spin-off. Very thin float; treat as structural, not a conviction signal.
$AIFU ·
AIFU Inc. (China insurance-agency platform (formerly Fanhua)) — 56.12% [Med]
Zhang Zack (individual, controlling shareholder)
Why: A majority-control holder disclosing a 56% stake — usually a control change or consolidation step rather than an outside thesis. Watch for any take-private or restructuring follow-on.
$GAUZ ·
Gauzy Ltd. (smart-glass / light-control materials maker) — 50.0% [Med]
Manieu Alexandre Weinstein (individual investor)
Why: An individual reporting half the company is a control-level stake — likely tied to a financing or control transaction; check the filing’s Item 4 before reading it as bullish.
$VISM ·
Visium Technologies, Inc. (micro-cap cybersecurity analytics) — 48.8% [Med]
Adler Bo Niclas (individual, 10%+ owner (also bought ~$350k on Form 4))
Why: Same holder also filed an open-market buy, so the 13D and Form 4 point the same way — but it’s a micro-cap with very low liquidity.
$XYF ·
X Financial (China online consumer-lending platform) — 47.97% [Med]
Mangrove Coast Investment Ltd (founder-linked holding vehicle)
Why: Founder-side vehicle restating a near-control stake; often tied to buybacks or a possible take-private in US-listed China names. Low signal on its own.
$CDLR ·
Cadeler plc (offshore wind-turbine installation vessels) — 30.77% [Med]
BW Altor Pte. Ltd. (BW Group (Sohmen family) investment arm)
Why: Long-standing anchor shareholder disclosing ~31% — a strategic holder, not a new activist. Read as stability of the anchor stake amid offshore-wind sentiment swings.
💰 INSIDER BUYS
$MDGL ·
Madrigal Pharmaceuticals, Inc. (MASH/fatty-liver drug Rezdiffra): BAKER BROS. ADVISORS LP (director) bought $35.0M. Why: Biotech’s best-known long-only fund adding to a core 6%-of-book position — a strong conviction add on the Rezdiffra launch ramp.
$KOD ·
Kodiak Sciences Inc. (retinal-disease biologics): BAKER BROS. ADVISORS LP (director + 10% owner) bought $24.3M. Why: Baker keeps buying after this year’s big run in KOD, signalling it expects more upside from the late-stage eye-disease readouts; risk is a binary data/approval path.
$KMI ·
KINDER MORGAN, INC. (largest US natural-gas pipeline operator): KINDER RICHARD D (exec chairman + 10% owner) bought $15.0M. Why: Co-founder’s latest in a run of large open-market buys — a steady vote of confidence in gas-demand growth (LNG, data centres).
$ANVS ·
Annovis Bio, Inc. (Alzheimer’s/Parkinson’s small-molecule biotech): Hoffman Michael B (chairman/director) bought $5.0M. Why: By far the chairman’s largest buy after a string of smaller ones; supports the stock ahead of Phase 3 buntanetap data, but it’s a single-asset micro-cap.
$CVS ·
CVS HEALTH Corp (pharmacy, PBM and Aetna insurer): Shah Prem S (officer) bought $2.0M. Why: Senior exec buying right after the 4 Nov Q3 beat ($2.09 vs $1.67 est.) — management backing the turnaround.
$MXF ·
MEXICO EQUITY & INCOME FUND INC (closed-end Mexico equity fund): Saba Capital Management, L.P. (10% owner) bought $0.50M. Why: Saba’s classic closed-end-fund discount activism — accumulating to push for tenders/liquidity events.
$YPF ·
YPF SOCIEDAD ANONIMA (Argentina’s state-controlled oil & gas major): Francos Guillermo Alberto (director) bought $0.36M. Why: Director buying the Argentina energy/Vaca Muerta story; political risk remains the swing factor.
$VISM ·
VISIUM TECHNOLOGIES, INC. (micro-cap cybersecurity analytics): Adler Bo Niclas (10% owner) bought $0.35M. Why: Same holder as the 48.8% 13D above.
$KYN ·
Kayne Anderson Energy Infrastructure Fund, Inc. (closed-end midstream energy fund): Baker James C (director + officer) bought $0.33M. Why: Fund chief buying his own vehicle — modest but aligned with the midstream yield thesis.
$JOF ·
JAPAN SMALLER CAPITALIZATION FUND INC (closed-end Japan small-cap fund): Saba Capital Management, L.P. (10% owner) bought $0.30M. Why: Second Saba closed-end-fund discount play today.
📊 Rest: +4 other 13D filings today (low conviction / small stakes / control & SPAC-sponsor filings) — NIP Group (NIPG) ×2, Silvia (SVIAW), Braskem (BAK, Carlos Slim 4.0%).
Research only — not investment advice. Thursday, November 5, 2026
📈 Activist & Insider Signals — Thu 5 Nov 2026 filings
2 Schedule 13Ds scanned · 941 Form 4s scanned · 1 roster hit · 19 qualifying insider buyers
🎯 PRIORITY (roster names)
Third Point Private Capital Income Fund (Third Point's new private-credit/income vehicle) — 100.0% [High] · roster: Daniel Loeb / Third Point
Third Point LLC (Dan Loeb's event-driven activist hedge fund, ~$20B AUM) — filed SCHEDULE 13D · 13FScore 39/100
Why: Structural, not a stock signal — Loeb is seeding his own private-capital funds (same day Form 4s: Loeb bought $9.7M of Third Point Private Capital Partners and $4.0M of the Income Fund). No tradable equity; it shows Third Point pushing further into private credit. Book: 39 pos, top-10 61.7%.
🔍 EMERGING (high-conviction, not on roster)
$SKFG ·
Stark Focus Group, Inc. (OTC micro-cap shell; apparel/drone pivots, going-concern flag) — 45.23% [Med]
MJG Polo LLC (private holding company, now listed as controlling parent, ~undisclosed AUM)
Why: Control-holder 13D on a tiny OTC shell — typical of a reverse-merger setup; watch for a business injection. Risk: going-concern doubt, illiquid, highly speculative.
💰 INSIDER BUYS
$LYEL ·
Lyell Immunopharma (T-cell therapies for cancer): ARCH Venture Fund XIII + ARCH Venture Partners IX (10%-owners) bought $25.0M [CLUSTER of 2 (same ARCH purchase)]. Why: Lead VC writing a fresh $25M check, likely a financing tranche after Lyell's 2025–26 milestone-based PIPE — insider money backing the CAR-T pipeline. Risk: dilution, clinical readouts..
$ETRA ·
Electra Therapeutics (precision immunology antibodies; Sept-2026 IPO): OrbiMed Advisors + Carl Gordon (director/10%-owner, OrbiMed) bought $3.6M [CLUSTER of 2 (same OrbiMed purchase)]. Why: Lead VC adding after a $350M IPO that traded below its $15 price — pre-IPO conviction carried into public markets; lead drug in Phase 2/3 for sHLH. ·
news.
$LBTY ·
Liberty Global (European cable/broadband holding company): Enrique Rodriguez (EVP, CTO) + Mike Fries (CEO) bought $3.03M combined [CLUSTER of 2]. Why: CEO's first sizable open-market buy in years (110k shares ~$9.37) alongside the CTO — management signalling the stock is too cheap amid its break-up/spin-off strategy..
$COUR ·
Coursera (online learning platform, merging with Udemy): Pale Fire Capital SE (10%-owner) bought $31.5M. Why: Czech investor (Jan Barta) aggressively adding above 10% across three days at ~$3.72 — deep-value bet on the Udemy combination. Risk: merger integration and AI pressure on ed-tech..
$CRBG ·
Corebridge Financial (US life insurance and annuities): Nippon Life Insurance (10%-owner) bought $12.9M. Why: Strategic owner keeps creeping its stake up — supportive floor and long-run strategic interest..
$GLXY ·
Galaxy Digital (crypto trading, asset management and data centers): Mike Novogratz (CEO, director, 10%-owner) bought $9.9M. Why: Founder-CEO buying ~$10M in his own name — a strong personal vote on the crypto/AI-datacenter story after a sell-off. Risk: crypto beta..
$PAM ·
Pampa Energy (Argentine power and gas producer): Damian Mindlin (VP, controlling family) bought $2.6M. Why: Controlling family keeps adding — conviction in Argentina's energy reforms and Vaca Muerta gas growth..
$TRAD ·
APEX Tech Acquisition (blank-check SPAC): Shaoren Liu (CEO/CFO, 10%-owner) bought $2.1M. Why: Sponsor-CEO buying into his own SPAC — usually supporting trust value ahead of a deal; little signal until a target is named..
$BXMT ·
Blackstone Mortgage Trust (commercial real-estate lender): Tim Johnson (CEO) bought $1.04M. Why: CEO buying as the CRE loan book stabilises — insider view that the dividend and book value are safe..
$FBRT ·
Franklin BSP Realty Trust (commercial mortgage REIT): Richard Byrne (Chairman/CEO) bought $1.0M. Why: CEO buying a discounted mortgage REIT..
$TTMI ·
TTM Technologies (PCBs for AI servers and defense): Wajid Ali (director) bought $632K. Why: Director adds to an AI-infrastructure supplier..
$BKR ·
Baker Hughes (oilfield services and LNG/power equipment): John Rice (director) bought $531K. Why: Ex-GE vice-chair director buying the energy-tech transition story..
$SPXC ·
SPX Technologies (HVAC and detection equipment): Brian Deck (director) bought $493K. Why: Director buy in a data-center cooling beneficiary..
$CLX ·
Clorox (household consumer products): Pierre Breber (director) bought $400K. Why: Director (ex-Chevron CFO) buying a beaten-down staple..
Carlyle Credit Solutions (private-credit BDC): Thomas Hennigan (CFO/President) bought $381K. Why: Officer buying the firm's own credit vehicle..
$LBRT ·
Liberty Energy (frac services and power generation): Ron Gusek (CEO) bought $377K. Why: CEO buying the oilfield-to-power pivot..
$MXF ·
Mexico Equity & Income Fund (closed-end fund): Saba Capital (10%-owner) bought $314K. Why: Saba's usual discount-to-NAV activism..
$FLOC ·
Flowco Holdings (oil-well production equipment): Jonathan Fairbanks (director/10%-owner) bought $293K. Why: Large holder adding..
$DGICA ·
Donegal Group (regional P&C insurer): Donegal Mutual (10%-owner, parent) bought $282K. Why: Parent mutual's routine creeping buys..
📊 Rest: no other 13D filings today (both 13Ds shown above).
Research only — not investment advice. Wednesday, November 4, 2026
📈 Activist & Insider Signals — Wed 4 Nov 2026 filings
7 Schedule 13Ds scanned · 1,239 Form 4s scanned · 0 roster hits · 14 qualifying insider buyers
🔍 EMERGING (high-conviction, not on roster)
Constitution Capital Access Fund (private-equity access interval fund) — 63.6% [Med]
Universities Superannuation Scheme (UK university pension scheme, ~£75B AUM)
Why: Structural, not activist: a giant pension seeding/anchoring a private-markets fund. No tradable equity — informational only.
$BHAIU ·
BHAV Acquisition Corp II (blank-check SPAC) — 28.17% [Med]
BHAV Partners II LLC (the SPAC's sponsor entity, ~n/a AUM)
Why: Routine sponsor 'founder share' 13D after the IPO — no signal until a merger target is named.
$PRSO ·
Peraso Inc. (mmWave wireless chips for 5G/fixed wireless) — 19.99% [Med]
Nant Capital, LLC (Patrick Soon-Shiong's family investment vehicle, ~multi-$B AUM)
Why: Exactly 19.99% suggests a negotiated strategic/private-placement stake capped below the 20% shareholder-vote limit — a micro-cap with a deep-pocketed new anchor. Risk: dilution and thin float.
$YCBD ·
cbdMD, Inc. (CBD wellness consumer products) — 15.9% [Med]
Akretive Holdings LLC (little-known private holding company, ~undisclosed AUM)
Why: New, unknown holder at ~16% of a sub-$20M CBD roll-up that has been doing small acquisitions — watch for a control or financing push. Risk: tiny, cash-burning issuer.
$VVR ·
Invesco Senior Income Trust (closed-end leveraged-loan fund) — 5.18% [Med]
Saba Capital Management, L.P. (Boaz Weinstein's closed-end-fund activist, ~~$5B AUM) · 13FScore 85/100
Why: Classic Saba playbook: buy a CEF trading below NAV, then push for a tender, liquidation or conversion to close the discount. Book: 344 pos, top-10 41.6%.
💰 INSIDER BUYS
$ASPE ·
Aspen Neuroscience, Inc. (Parkinson's autologous cell therapy): OrbiMed Advisors + Peter A. Thompson (director/10%-owner, OrbiMed) bought $15.0M [CLUSTER of 2 (same OrbiMed purchase)]. Why: Lead VC buying in the Oct-30 IPO, which priced at the low end ($15) — pre-IPO conviction carried into public markets; Phase 3 start not until H2 2027. ·
news.
$UPBD ·
Upbound Group, Inc. (Rent-A-Center / Acima lease-to-own): Jeffrey Brown, Glenn Marino (directors) + Halim Khouri (officer) bought $1.04M combined [CLUSTER of 3]. Why: Three insiders buying together is the strongest kind of insider signal — board sees value in the beaten-down lease-to-own name..
$AN ·
AutoNation, Inc. (largest US auto dealer group): Mike Manley (CEO) + Thomas Szlosek (CFO) bought $1.33M combined [CLUSTER of 2]. Why: CEO and CFO buying together after earnings — management backing its buyback-heavy, used-car/finance story..
$KNOP ·
KNOT Offshore Partners LP (shuttle-tanker MLP): Trygve Seglem (director; controls sponsor Knutsen NYK) bought $43.5M. Why: Very large buy by the sponsor's owner; Knutsen NYK made a take-private bid in 2025 that was dropped in Mar-2026 — a renewed creep toward control is the catalyst to watch. ·
news.
$DOLE ·
Dole plc (global fresh-produce producer): Pale Fire Capital SE (10%-owner) bought $12.9M. Why: Czech activist (Jan Barta) keeps adding above 10% — pressure for value release/strategic action at a low-multiple produce company. ·
news.
$INTC ·
Intel Corp (x86 CPUs and foundry): Lip-Bu Tan (CEO/director) bought $9.7M. Why: CEO adds another ~$10M after his August buy — continued personal conviction in the foundry turnaround. ·
news.
$CRBG ·
Corebridge Financial (US life insurance and annuities): Nippon Life Insurance (10%-owner) bought $6.7M. Why: Strategic owner topping up its stake — supports the floor; possible longer-run path to a bigger holding..
$SCQCU ·
SPACCircle Acquisition Corp. (blank-check SPAC): Soumen Das (director/10%-owner) bought $2.67M. Why: Sponsor-related SPAC unit purchase — mechanical, low signal..
$LRN ·
Stride, Inc. (online K-12 education): Brian Shepherd (director) bought $1.67M. Why: Director buying after the stock's sharp post-earnings drop — a vote that the selloff overshot..
$CACC ·
Credit Acceptance Corp (subprime auto lender): Thomas Tryforos (director) bought $1.46M. Why: Long-time director adding to a heavy buyback compounder..
$LSCC ·
Lattice Semiconductor (low-power FPGAs): Ford Tamer (CEO/director) bought $1.0M. Why: CEO open-market buy — conviction in the AI-edge/datacenter FPGA cycle..
$HGV ·
Hilton Grand Vacations (timeshare operator): Mark Wang (CEO/director) bought $499K. Why: CEO buy at depressed valuation..
$JBLU ·
JetBlue Airways (US low-cost airline): Nik Mittal (director) bought $324K. Why: Director buying into a turnaround/balance-sheet repair story..
$MXF ·
Mexico Equity & Income Fund (closed-end Mexico equity fund): Saba Capital (10%-owner) bought $284K. Why: Saba adding to a discounted CEF — same discount-arbitrage playbook as VVR..
📊 Rest: +2 other 13D filings today (low conviction / small stakes: SDR Drone 2.7%, MSC Income Fund).
Research only — not investment advice.
Tuesday, November 3, 2026
🏛 Activist 13D & Insider-Buy Digest — 4 Nov 2026 (filings dated 3 Nov; 3 13Ds scanned, 1,723 Form 4 rows → 15 qualifying buys, 2 clusters)
🔍 EMERGING (high-conviction, not on roster)
$ADMT ·
ADM Tronics Unlimited, Inc. (NJ electronics & medical-device contract manufacturer, OTC) — 21.6% [Med]
Gregory D. Wasson (ex-Walgreens CEO, via Wasson Enterprise / G&K Investment Holdings family office) — filed SCHEDULE 13D
Why: Wasson's group anchored a ~$5M private placement at $0.10/share with 50% warrant coverage, takes board control alongside new independent chairman Klaus Kleinfeld (ex-Alcoa/Siemens CEO), and a 1-for-20 reverse split is planned — a change-of-control, strategic-pivot setup on a sub-$10M microcap. Risk: illiquid OTC name, heavy dilution, and the pivot itself is still undefined ·
news.
$PENG ·
Penguin Solutions, Inc. (AI/HPC infrastructure, memory & LED solutions; ex-SMART Global) — 9.1% [Med]
SK hynix Inc. (Korean memory-chip & HBM leader, strategic holder via HYAICO / SHIFTIX1 LLC) — filed SCHEDULE 13D
Why: the $200M 6% convertible preferred that SK Telecom bought in Dec 2024 now sits with an SK hynix unit, so the partner in the Jan 2025 AI-data-center collaboration is the direct holder; the issuer's forced-conversion right opens Dec 2026. Read it as a tightening strategic tie with the HBM leader rather than activism; risk is an eventual ~6.1M-share conversion overhang ·
news.
💰 INSIDER BUYS
$BA ·
Boeing Co (commercial jets & defense):
Tim Buckley (director, ex-Vanguard CEO) bought $998k at $171.55 +
Steven Mollenkopf (director, ex-Qualcomm CEO) bought $510k at $173.03 on 30 Oct [CLUSTER of 2]. Why: two heavyweight directors buying the 27 Oct post-earnings washout — shares hit ~$168, the lowest since Apr 2025, after a Q3 loss and a 737 delivery-target miss, down ~21% since late July. A board vote of confidence into the drawdown; risk is further 737/777X execution slippage ·
news.
John Hancock GA Senior Loan Trust (non-traded Manulife senior-loan fund):
Manufacturers Life Reinsurance Ltd +
Manulife Bermuda Branch (10%-owners) bought $31.0M + $12.2M at $16.12 NAV on 30 Oct [CLUSTER of 2]. Why: sponsor seeding its own general-account loan fund; not tradeable.
$MGM ·
MGM Resorts International (Las Vegas Strip, regional & Macau casinos, BetMGM):
Keith Meister (director; founder of Corvex Management, ~$3B activist fund) bought $51.7M (1.75M sh) at $28.92–$30.24 on 30 Oct–2 Nov. Why: the biggest buy of the day. Meister lifts his indirect stake to ~7.1M shares days after a weak Q3 (Strip RevPAR −8%, a rare quarterly loss) and after People Inc. withdrew its $18B+ go-private bid — but the amended voting agreement explicitly clears the way for aggressive buybacks. An activist-director doubling down near $30 on a stock that was $36 a year ago; risk is a prolonged Vegas slowdown ·
news.
$BBTX ·
Bambusa Therapeutics, Inc. (bispecific antibodies for atopic dermatitis & inflammation; IPO'd 30 Oct):
RA Capital Management, L.P. (director + 10%-owner; Boston biotech specialist, ~$10B AUM) bought $46.6M (2.95M sh) at the $16 IPO price. Why: the Series A lead converting pre-IPO conviction into a very large order in a $169M upsized deal; lead asset BBT001 posted Phase 1 proof-of-concept in July. Risk: early-stage, effectively single-asset biotech with a going-concern note, assets in-licensed from BioNTech's China unit ·
news.
$SIRI ·
Sirius XM Holdings Inc. (satellite radio & Pandora):
Berkshire Hathaway Inc (10%-owner) bought $26.9M (924k sh) at $28.89–$30.23 across 30 Oct–3 Nov. Why: Berkshire keeps adding (now ~125.7M shares, ~37% of the company) even with the stock near its 52-week high of $32.66 after a 13% weekly rally — the steady-buyer floor is intact. Risk: subscriber attrition; the stake is already so large that incremental buys say more about Berkshire's patience than about new information ·
news.
$LRN ·
Stride, Inc. (K-12 online schooling & career learning):
Dylan Haggart (new director; managing partner of activist Fivespan Partners) bought $17.6M (228k sh) at ~$75 on 30 Oct–3 Nov. Why: Fivespan won a board seat and a capital-allocation committee on 9 Oct and has now bought ~$30M in a month, averaging down from ~$79 — an activist with a seat and a buyback agenda pressing a de-rated stock. Risk: enrollment and school-funding policy swings ·
news.
$CRBG ·
Corebridge Financial, Inc. (AIG's spun-out life & retirement insurer):
Nippon Life Insurance Co (10%-owner; Japan's largest life insurer) bought $7.9M at $35.31 on 30 Oct under a 10b5-1 plan. Why: programmatic accumulation on top of the 20% stake bought from AIG at $31.47 — a steady strategic bid under the stock, not a reaction to news.
$PLBY ·
Playboy, Inc. (Playboy brand licensing & Honey Birdette):
Docler Holding S.a r.l. (director + 10%-owner; Luxembourg parent of Byborg Enterprises) bought $5.0M (4.76M sh) at $1.05 on 30 Oct. Why: the Byborg affiliate is backstopping Playboy's buyback of Fortress's ~16.6M shares at $1.05 — a ~28% discount to market — so a strategic holder is taking out a forced seller cheaply and pushing its stake toward ~17%+. Risk: micro-cap with debt reduction still ahead ·
news.
$SITE ·
SiteOne Landscape Supply, Inc. (largest US wholesale landscape-products distributor):
Doug Black (chairman & CEO) bought $1.0M (9,100 sh) at $110.68 on 30 Oct. Why: third open-market buy since August (then $96–$102), now adding above $110 right after the 28 Oct Q3 print — a CEO averaging UP is a stronger tell than one averaging down. Risk: housing and landscaping demand softness.
Smaller buys (Med):
$CAT Caterpillar —
James Fish (director; Waste Management CEO) $620k at $620.39 on 2 Nov ·
$LKQ LKQ Corp —
Andrew Clarke (director) $400k at $18.35 ·
$TRTX TPG RE Finance Trust —
Wendy Silverstein (director) $253k at $6.51 ·
Calamos Aksia Hedged Strategies Fund sponsor seed $728k (non-traded, not tradeable).
📊 Rest: +1 other 13D filing today (SPACCircle Acquisition sponsor 34.5% control filing — SPAC-sponsor, low conviction).
Research only — not investment advice. Monday, November 2, 2026
🏛 Activist 13D & Insider-Buy Digest — 3 Nov 2026 (filings dated 2 Nov; 8 13Ds scanned, 41 Form 4 rows → 17 qualifying buys)
🔍 EMERGING (high-conviction, not on roster)
$DIN ·
Dine Brands Global, Inc. (IHOP & Applebee's franchisor) — 4.3% [Med] · below the 5% screen but included: it is a takeover bid
Arkhouse Management Co. LP (NYC real-estate-focused activist, the Macy's bidder, ~$1B AUM) +
Cobblers Cove Capital LP (1.4%) — filed SCHEDULE 13D
Why: Arkhouse and Cobblers Cove jointly sent a non-binding $39/share take-private proposal on 26 Oct and say they have ~20% economic exposure via swaps; Dine answered with a poison pill (10% activist trigger). Event-driven: watch for a raised bid, a proxy fight or the board engaging; risk is the board stonewalling and the stock giving back the bid premium ·
news. Book: 16 pos, top-10 92.6%
Hamilton Lane Venture Capital & Growth Fund (evergreen '40-Act fund holding Cerebras, Toast, IonQ, Chime stakes) — 17.6% [High]
Hamilton Lane Advisors LLC (private-markets asset manager, ~$140B AUM) — filed SCHEDULE 13D · 13FScore 18/100
Why: the adviser bought $36.5M of its own non-traded fund at $20.50 NAV — sponsor seed capital, a structural filing rather than an activist one. Interesting only as a read-through: Hamilton Lane keeps putting house money behind a late-stage venture book (Cerebras, Chime, IonQ). Not tradeable; no ticker. Book: 14 pos, top-10 99.6%
$MSGR ·
MSG Rangers Corp. (New York Rangers, spun out of MSG Sports 26 Oct) — 13.2% [Med]
James L. Dolan (Dolan family controlling shareholder, exec chairman & CEO) — filed SCHEDULE 13D
Why: a control filing mirroring Dolan's pre-spin MSG Sports stake, not new buying. The spin itself is the event — a pure-play NHL franchise at ~$190 with the Knicks separated out (MSGK); sports-franchise scarcity value vs. the usual Dolan governance discount ·
news
$NARA ·
Narragansett Bancorp, Inc. (BayCoast Bank, $2.9B-asset MA/RI community bank, IPO'd 2 Nov at $10) — 55.0% [Med]
Narragansett Financial Corp (mutual holding company parent) — filed SCHEDULE 13D
Why: structural — the MHC keeps 55% after the $91M minority stock offering. The trade, if any, is the classic thrift-conversion playbook: these deals price near tangible book and a second-step conversion or buyback usually follows after year one; risk is thin liquidity and a rate-sensitive balance sheet ·
news $VDTA ·
Vertical Data Inc. (Las Vegas AI/HPC data-center infrastructure, OTC) — 18.7% [Med]
Deven Soni (founder, chairman & CEO) — filed SCHEDULE 13D
Why: founder control stake on a thinly traded OTC AI-infrastructure microcap, not outside activism. Treat as a watch-only insider-ownership data point; liquidity and disclosure risk are high.
💰 INSIDER BUYS
$ASPE ·
Aspen Neuroscience, Inc. (autologous cell therapy for Parkinson's, IPO'd 30 Oct):
ARCH Venture Fund X +
ARCH Venture Partners XIV (10%-owners) bought $20.0M + $18.0M at the $15 IPO price [CLUSTER of 2]. Why: ARCH, the lead pre-IPO backer, put another $38M in at an IPO priced at the low end of its range — insider conviction on sasineprocel (Phase 1/2a, Phase 3 dosing targeted 2H27); risk is binary clinical data and a 180-day lock-up overhang ·
news.
$BBTX ·
Bambusa Therapeutics, Inc. (bispecific antibodies for atopic dermatitis/COPD, IPO'd 30 Oct):
Helmut Jeggle (director & 10%-owner, via
Salvia Investment GmbH) bought $6.0M at the $16 IPO price [CLUSTER of 2 filers, same purchase]. Why: Jeggle (ex-BioNTech chair, Strüngmann-family money) anchoring an upsized $169M biotech IPO is a credibility signal for BBT001 (IL-4Rα x IL-31) vs. Dupixent; risk is early-stage data and IPO-window sentiment ·
news.
$ROL ·
Rollins Inc (Orkin pest-control services):
LOR Inc / R. Randall Rollins Voting Trust (10%-owners) bought $50.0M — 1,444,402 sh at $34.59 avg on 29 Oct [joint filing, 1 purchase]. Why: the Rollins family (37.9% holder) adding $50M on the open market after a pullback is the largest insider buy of the day; a defensive compounder where family buying has historically marked floors. Risk: low float turnover, premium multiple.
$CRBG ·
Corebridge Financial, Inc. (AIG-spun life & retirement insurer):
Nippon Life Insurance Co (10%-owner, ~22%+) bought $8.75M at $35.50. Why: Nippon Life keeps accumulating under a trading plan on top of its $3.8B block from AIG — a strategic holder creeping up ahead of AIG's exit window (Dec 2026); supports a floor and keeps full-takeover optionality alive ·
news.
Friday, October 30, 2026
🗓 Alpha-Investor Signal Digest — 2026-10-31
(filings of 2026-10-29 & 2026-10-30 · 7 13Ds scanned · 10 unique qualifying insider buys)
🔍
EMERGING (high-conviction, not on roster)
$LUDG ·
Ludwig Enterprises (OTC mRNA inflammation-biomarker diagnostics developer) — 74.9% [Med]
FOXO Technologies (microcap health/insurtech holding co, strategic buyer, no 13F AUM)
Why: Control deal, not open-market — FOXO signed (Oct 29) to buy majority-voting preferred plus Ludwig notes and holds irrevocable proxies pre-closing. Catalyst: closing; risk: conditions include FOXO's Nasdaq listing approval and a financing, and Ludwig's Revealia swab is not FDA-cleared.
$ZVIA ·
Zevia PBC (zero-sugar stevia soda & drinks brand) — 16.1% [Med]
Bubble Holdings, LLC (affiliate of Brazilian PE firm GP Investments)
Why: Strategic PIPE — bought $15M of convertible Series A preferred on Oct 22 (≈13.8M as-converted shares) with a further 5,000 pref due at a deferred closing tied to 2026 net sales ≥$172.5M and an EBITDA test. A PE sponsor with a growth-hurdled second tranche signals a turnaround bet; risk: conversion dilution, if hurdles are missed the second tranche falls away.
$LEE ·
Lee Enterprises (US local newspapers & digital media publisher) — 14.4% [Med]
Quint Digital Ltd (Indian listed digital-media investor (BSE: QUINTDIGITAL))
Why: Strategic holder from the Hoffmann-led $50M recap (bought at $3.25, later topped up ~$9) — the 13D refresh keeps it the #2 holder alongside chair David Hoffmann. Event angle: Hoffmann-era turnaround/possible take-private; risk: secular print decline and debt load. ·
news
$IVAI ·
Ives Ultra AI Opportunities (NYSE closed-end fund owning late-stage private AI cos) — 9.4% [Med]
YA II PN, Ltd. (Yorkville Advisors fund, Dan Ives’s merchant-bank partner)
Why: Structural/affiliated — Yorkville partnered with Ives on the merchant bank, so this ~9% stake after the $200M Sept 30 IPO is anchor capital rather than an activist bet. Risk: closed-end funds often drift to a NAV discount once IPO support fades. ·
news
$NNOX ·
Nano-X Imaging (Israeli low-cost digital X-ray & AI imaging) — 8.49% [Med]
Moshe Moalem (Nanox co-founder, individual holder)
Why: Co-founder switched from a passive 13G (7.56% in June) to a 13D at 8.49% (6.68M shares, personal funds) — moving to 13D can flag intent to influence the board/strategy. Purpose not yet public; risk: cash burn and slow commercial uptake of the Arc system.
💰
INSIDER BUYS $RAPP ·
Rapport Therapeutics (precision neurology drugs, epilepsy lead program): James Healy (director, via Sofinnova funds) bought $20.4M. Why: Sofinnova took ~970K shares at $21.00 in Rapport's ~$380M Oct 28 equity + convert financing — a large insider fund backing a raise priced below the $26 2025 follow-on. Risk: dilution from the offering and the convertible notes. ·
news
$CRBG ·
Corebridge Financial (US life insurer & annuities): Nippon Life Insurance Co (10%-owner) bought $14.9M over two days ($6.3M Oct 29 filing + $8.7M Oct 30). Why: Fourth straight digest with the strategic owner buying on market — a steady, accelerating bid under the stock. Risk: rate/annuity-spread sensitivity.
$TFC ·
Truist Financial (Southeast US super-regional bank): Michael Lyons (CEO & director) bought $1.2M. Why: Second ~$1M+ open-market buy (~$48.35) since he became CEO, after the September purchase that followed the $5.5B auto-loan exit — a new CEO repeatedly backing his restructuring. Risk: credit cycle, NII pressure.
$DINO ·
HF Sinclair (US oil refiner, renewables & lubricants): Franklin Myers (director+officer) bought $1.1M. Why: Repeat buyer — follows his ~$1.3M August purchase; serial buying by the top executive into refining-margin volatility. Risk: crack-spread swings.
$PNFP ·
Pinnacle Financial Partners (Southeast US regional bank): David Ingram (director) bought $992K. Why: Sizable director buy — mild positive alongside bank peers.
$XYL ·
Xylem (water pumps, treatment & metering tech): D. Christian Koch (director) bought $986K. Why: Rare ~$1M director open-market buy in a large-cap — a confidence vote.
$LYCA ·
Lycia Therapeutics (food-allergy biotech, Oct 23 IPO):
Venrock Healthcare Capital Partners III (10%-owner) bought $645K. Why: Lead Series C VC (~9% post-IPO, board seat) still adding after the upsized $317.5M IPO at $18 and a ~50–67% day-one pop. Risk: Phase 1 data not due until 2027. ·
news
$SAMG ·
Silvercrest Asset Management (wealth manager for ultra-high-net-worth families): Equinox Partners Investment Management (10%-owner) bought $349K. Why: Value holder keeps adding to a 10%+ stake — slow accumulation in a small-cap.
📊 Rest: +2 other 13D filings (de-SPAC merger-consideration stakes): Paul Lichty, Forge Nano founder/CEO (7.5%, $NANO); Benjamin Tan in Bradbury Capital (7.15%, $BBCI). Excluded: SPACCircle Acquisition (SCQCU) director Soumen Das — $2.7M of sponsor private-placement units at IPO, not an open-market buy. Note: the Form 4 feed repeated several buys (31 rows → 10 unique); deduped above.
Research only — not investment advice. Thursday, October 29, 2026
📊 Activist & insider digest — Thursday, October 29, 2026
4 13D filings · 7 qualifying insider buys scanned🔍 EMERGING (high-conviction, not on roster)
Wednesday, October 28, 2026
🗓 Alpha-Investor Signal Digest — 2026-10-29
(filings of 2026-10-28 · 3 13Ds scanned · 10 qualifying insider buys)
🔍
EMERGING (high-conviction, not on roster)
$NEWH ·
NewHydrogen (heat-based ThermoLoop green-hydrogen tech) — 42.7% [Med]
SunHydrogen (OTC solar-hydrogen developer, strategic corporate holder, no 13F AUM)
Why: Strategic investment announced Oct 26 pairs SunHydrogen's solar-to-hydrogen panels with NewHydrogen's thermal process — a near-control stake that could lead to a full combination. Risk: two pre-revenue OTC microcaps, dilution-prone. ·
news
$SWBI ·
Smith & Wesson Brands (US firearms maker, now owns Savage Arms) — 16.7% [Med]
JDH Capital I, L.P. (private holding co, former Savage Arms owner)
Why: Deal-driven, not open-market — JDH took ~9M SWBI shares (valued ~$13.62) plus $37.5M cash for Savage Arms (closed Oct 21) and gets a board seat. A 16.7% holder with a director aligns it with the merger synergies; watch for lock-up expiry as a future overhang. ·
news
$BKU ·
BankUnited (Florida-based regional commercial bank) — 5.0% [Med]
HoldCo Asset Management (bank-focused activist hedge fund, ~$1.4B 13F book) · 13FScore 49/100
Why: HoldCo has built from ~0.9M to ~3.5M+ shares and now crossed 5% with a 13D — it argues BKU trades without a "Florida premium" and typically pushes banks toward a sale. Catalyst: sale/strategic-review pressure; risk: management stays standalone. ·
news. Book: 29 pos, top-10 88.7%
💰
INSIDER BUYS
$TTMI ·
TTM Technologies (PCBs & RF for AI data centers/defense): Wajid Ali (director) bought $902K; Edwin Roks (President & CEO) bought $440K [CLUSTER of 2]. Why: Both bought Oct 28 at ~$88–91, far below the CEO's August buy at ~$112, alongside a just-finished ~1.16M-share buyback and a new $100M program — insiders leaning in after a ~20% pullback. Risk: AI-capex cycle sentiment.
$GOLD ·
Gold.com (precious-metals trading & e-commerce, ex-A-Mark): Tether Global Investments Fund (10%-owner) bought $3.9M. Why: Stablecoin issuer keeps adding 100K-share blocks (~$39.4, below its $44.50 Feb entry) on top of its ~12% strategic stake — a deep-pocketed holder averaging down. Risk: gold-price swings. ·
news.
$ACN ·
Accenture (global IT consulting & outsourcing): Julie Sweet (Chair & CEO) bought $3.0M. Why: A rare open-market buy (12,200 sh at ~$246) by a CEO who usually only sells or buys tiny plan lots — a strong confidence signal in a stock pressured by AI-disruption fears. Risk: slowing consulting demand.
$CRBG ·
Corebridge Financial (US life insurer & annuities): Nippon Life Insurance Co (10%-owner) bought $6.4M. Why: Third straight digest with the strategic owner buying on market (~$34.95) — a steady bid under the stock.
$XBIT ·
XBiotech (antibody drug developer): John Simard (founder/CEO, director+10%-owner) bought $711K. Why: Controlling founder adding at ~$1.93 — alignment, but a closely held stock. Risk: thin liquidity, early-stage pipeline.
$RCT ·
RedCloud Holdings (B2B retail-supply trading platform for emerging markets): Nikolaus Senn (director+10%-owner) bought $425K. Why: Major holder buying 1.7M shares at $0.25 — supportive, but a penny stock. Risk: listing compliance, dilution.
$HBAN ·
Huntington Bancshares (Midwest regional bank): James Rollins III (director) bought $254K. Why: Modest director buy at ~$19.43 — small, mild positive.
Bluerock Private Real Estate Fund (non-listed real-estate interval fund): Ramin Kamfar (director, Bluerock founder) bought $2.2M. Why: Founder adding to his own fund — alignment, not a tradable stock.
Willow Tree Capital Corp (middle-market senior-loan BDC, not exchange-listed): Liberty Mutual Holding (10%-owner) bought $529K. Why: Institutional anchor topping up — not a tradable stock.
📊 Rest: no other 13D filings today (all 3 shown above). Excluded: a LeonaBio (LONA) Form 4 coded as a purchase that is actually a warrant exercise.
Research only — not investment advice. Tuesday, October 27, 2026
🗓 Alpha-Investor Signal Digest — 2026-10-28
(filings of 2026-10-27 · 0 13Ds scanned · 12 qualifying insider buys)
💰
INSIDER BUYS
$LYCA ·
Lycia Therapeutics (autoimmune/allergy biotech, IPO’d Oct 23): Venrock Healthcare Capital Partners III (10%-owner) bought $37.7M. Why: Lead Series C backer kept buying in the aftermarket (~$26.84 avg vs $18 IPO price) — insiders adding above the IPO price signals conviction into the first data readouts. Risk: richly valued early-stage biotech after a ~50% IPO pop. ·
news.
$MSM ·
MSC Industrial Direct (industrial MRO distributor): Mitchell Jacobson (director+10%-owner) bought $29.0M. Why: Co-founder/ex-chairman back for a much bigger bite (~$116/sh vs ~$85 buys a year ago) — founder doubling down on the industrial-recovery story. Risk: buying after a large run-up.
$CRBG ·
Corebridge Financial (US life insurer & annuities): Nippon Life Insurance Co (10%-owner) bought $20.2M. Why: Strategic owner keeps adding on market (second straight daily digest) — steady bid under the stock as AIG’s remaining stake comes out of lock-up.
$LRN ·
Stride (online K-12 & career education): Dylan Haggart (director (Fivespan Partners founder)) bought $12.2M. Why: The ex-ValueAct activist just joined the board via an Oct 9 cooperation deal that set up a capital-allocation committee — a $12M personal/fund buy points to buybacks or balance-sheet moves ahead. Risk: enrollment/regulatory scrutiny of virtual schools. ·
news.
$SRRK ·
Scholar Rock (muscle-targeting biotech (apitegromab for SMA)): Srinivas Akkaraju (director, Samsara BioCapital) bought $12.0M. Why: Repeat buyer — he put ~$15M+ in a year ago and is adding again at ~$41.6; biotech-specialist conviction in the apitegromab approval/launch path. Risk: binary regulatory/manufacturing timing.
$CTEV ·
Claritev (healthcare cost-management & payments tech (ex-MultiPlan)): Ares Management (10%-owner) bought $1.7M. Why: Ares (~11% holder) nudging its stake higher around $24 — a credit-heavy sponsor adding equity suggests comfort with the post-refinancing turnaround. Small relative to its position.
$NPB ·
Northpointe Bancshares (Michigan bank, mortgage-warehouse lender): Charles Alan Williams (Chairman & CEO) bought $1.5M. Why: CEO is a serial buyer and is now averaging down (~$15.32 vs ~$17 in August) — insider sees value below recent levels. Risk: mortgage-volume sensitivity.
$PLUR ·
Pluri (Israeli cell-based tech platform): Alexandre Weinstein Manieu (director+10%-owner) bought $1.3M. Why: Chairman keeps funding the company (third injection in a year, now at $1.50) — support, but it is financing more than a market signal. Risk: dilution and Nasdaq listing compliance. ·
news.
Willow Tree Capital Corp (middle-market senior-loan BDC, not exchange-listed): Hershey Trust (for Milton Hershey School) (10%-owner) bought $1.2M. Why: Endowment steadily accumulating (~3.07M shares now) — alignment signal, not a tradable stock.
$AIOK ·
AI OKTO (LPG-carrier shipping spin-off from Toro, listed Oct 9): Petros Panagiotidis (CEO, ~74% owner) bought $1.1M. Why: Controlling CEO buying right after the spin-off (~$12.88) — supports the thin float early on. Risk: tiny, controlled float and volatile pricing. ·
news.
$DAIO ·
Data I/O (device-programming systems for electronics makers): Red Oak Partners (10%-owner) bought $1.0M. Why: Microcap activist adding at $2.68 while the company pursues a transformational acquisition — event-driven bet on the deal. Risk: illiquid microcap, deal execution.
$TIPT ·
Tiptree (insurance & specialty-finance holding co): Michael Barnes (Chairman & CEO, ~27% owner) bought $502K. Why: Controlling holder topping up under a standing purchase plan — routine alignment, modest size.
📊 Rest: no 13D filings in yesterday's feed.
Research only — not investment advice. Monday, October 26, 2026
🗓 Alpha-Investor Signal Digest — 2026-10-27
(filings of 2026-10-26 · 8 13Ds scanned · 11 qualifying insider buys)
🔍
EMERGING (high-conviction, not on roster)
$AZUXY ·
Azul SA (Brazilian low-cost airline, post-restructuring) — 7.9% [High]
American Airlines Group Inc. (US major airline, strategic investor)
Why: Strategic, not activist: AA exercised warrants for ~31.8M new shares ($100M) after Brazil CADE cleared it on Oct 7, and got a board seat. Joins United (~8%) as a holder — a vote of confidence in Azul’s post-Chapter 11 recovery; risk is BRL/fuel and thin equity cushion. ·
news
$CPSH ·
CPS Technologies Corp (metal-matrix composites for EV/defense/rail) — 6.46% [High]
Global Value Investment Corp. (Milwaukee value activist (Jeff Geygan)) · 13FScore 40/100
Why: GVIC targets out-of-favor microcaps and pushes governance changes (RMCF board seat, StealthGas campaign) — a new 6.5% stake flags a likely engagement/board-seat push at a tiny-float name. Risk: illiquid microcap, GVIC’s cloned 13F book has lagged (40/100).
$ALDS ·
APPlife Digital Solutions (micro-cap app developer) — 57.4% [Med]
Mammoth Crest Capital LLC (private investment vehicle)
Why: A 57% stake is effectively a control position — likely a recap/change-of-control event rather than an investable activist trade. Shell-company risk is high.
$CTY ·
City Therapeutics (RNAi therapeutics biotech) — 25.6% [Med]
ARCH Venture Fund XII, L.P. (top-tier biotech venture capital)
Why: Founder-VC holding carried through the IPO — continuing pre-IPO conviction, not a fresh open-market buy. Watch lock-up expiry as the main overhang.
$CTRVP ·
Hepion Pharmaceuticals (clinical-stage biotech shell) — 19.9% [Med]
Gravitas Collective Corp. (newly formed holding company)
Why: 19.9% (just under the 20% Nasdaq approval threshold) by a new entity suggests a reverse-merger/recap setup. Highly speculative.
PRIMECAP Odyssey Funds (mutual fund trust) — 10.5% [Med]
Gregory Todd Molinelli (individual (PRIMECAP-affiliated))
Why: Mutual-fund share-class ownership filing (with Alfred W. Mordecai at 6.6%) — structural, not a stock signal.
$SNES ·
SenesTech, Inc. (rodent fertility-control products) — 5.4% [Med]
Justin Michael LeBeau (individual investor)
Why: Individual crossing 5% in a nano-cap — watch for follow-on buys or a board push; otherwise low signal.
💰
INSIDER BUYS
Blackstone Multi-Strategy Hedge Fund L.P. (Blackstone multi-manager hedge-fund vehicle): Querrey Kimberly K. (director) $7.0M + Collins Philip Daniel (director) $2.0M + Abrahams Riad M (director+officer) $795K + Desai Ravi Rajendra (officer) $400K [CLUSTER of 4]. Why: Board/officers putting ~$10.2M into their own non-traded fund — alignment signal, not a tradable stock.
$GPI ·
Group 1 Automotive (auto dealership group (US/UK)): Conifer Management, L.L.C. (10%-owner) bought $24.2M. Why: Conifer keeps accumulating (big May buy, Sept adds) and gets a board seat Nov 1 — a growing, engaged holder. ·
news
$CRBG ·
Corebridge Financial (US life insurer & annuities): NIPPON LIFE INSURANCE CO (10%-owner) bought $8.7M. Why: Strategic owner (~21.6% since the 2024 AIG deal) adding on market — supportive as AIG’s 9.9% lock-up nears its end ~Dec 2026. ·
news
$BPRE ·
Bluerock Private Real Estate Fund (interval real-estate fund): KAMFAR RAMIN (director) bought $2.1M. Why: Bluerock founder buying his own fund — alignment, limited trading signal.
$PRTA ·
Prothena Corp (neuro/amyloid biotech): SCULLY WILLIAM P (10%-owner) bought $1.2M. Why: Serial buyer all year (June, Aug, Sept, now again) — persistent insider conviction in a beaten-down biotech. ·
news
$OPTU ·
Optimum Communications (US cable/broadband (ex-Altice USA)): SUBIN NEIL S (10%-owner) bought $1.2M. Why: Large holder adding to a levered cable name — a deep-value bet on deleveraging; debt load is the key risk.
$KRRO ·
Korro Bio (RNA-editing biotech): Lynx1 Capital Management LP (10%-owner) bought $885K. Why: Biotech specialist fund averaging into a 10%+ position.
$THRM ·
Gentherm (auto thermal/seat-comfort tech): MASCARENAS PAUL ANTHONY (director) bought $533K. Why: Meaningful director buy at an auto supplier.
$CITR ·
CitroTech Inc. (fire-retardant products): HUFF CRAIG A (director+10%-owner) bought $500K. Why: Controlling holder adding to a micro-cap.
$LEO ·
BNY Mellon Strategic Municipals (closed-end muni bond fund): Saba Capital Management, L.P. (10%-owner) bought $369K. Why: Classic Saba closed-end-fund discount activism — catalyst is a tender/liquidation push.
$ACOG ·
Alpha Cognition (Alzheimer’s drug developer): Opaleye Management Inc. (10%-owner) bought $266K. Why: Small-cap healthcare fund topping up.
📊 Rest: +8 other 13D filings today (amendments / low conviction / small stakes / control filings).
Research only — not investment advice.Friday, October 23, 2026
📈 Alpha-Investor Signal Digest — 2026-10-24
Filings of 2026-10-23 · 3 13Ds scanned · 49 qualifying Form 4 rows (6 issuers)
🔍 EMERGING (high-conviction, not on roster)
$ABEO ·
Abeona Therapeutics (gene therapy; Zevaskyn for rare skin disease RDEB) — 6.1% [Med]
James Russell Revocable Trust (individual investor trust, Las Vegas, ~AUM n/a)
Why: Holder switched from passive 13G (5.3% in 2025) to a 13D, which can signal intent to engage with management; catalyst is Zevaskyn commercial ramp, risk is a slow launch and biotech dilution.
$BBCIW ·
Bradbury Capital Inc. (Malaysian e-voucher and digital payments, ex-SPAC) — 7.15% [Med]
ONG MEI YOONG (individual holder, likely de-SPAC insider, ~AUM n/a)
Why: Post-merger ownership disclosure after the TETE SPAC deal closed and listed on Nasdaq Oct 7; structural, not activist. Thin float and de-SPAC selling pressure are the main risk. ·
news
Oxford Park Income Fund, Inc. (private closed-end CLO equity/debt fund) — 24.8% [Med]
Oxford Gate Management, LLC (Oxford-affiliated manager, Greenwich CT, ~AUM n/a)
Why: Affiliated manager holding a large block of its own non-traded fund; structural, no tradable ticker or catalyst. ·
news
💰 INSIDER BUYS
$RENT ·
Rent the Runway (fashion rental subscription):
Nexus Capital +
STORY3 Capital (director+10%-owner, joint filing) bought $2.25M; CHS US Investments (10%-owner) bought $1.63M [CLUSTER of 3]. Why: The control group from the 2025 recapitalization is adding to its position, a sign it backs the turnaround; risk is leverage ($120M debt) and a small, illiquid float. ·
news
Blackstone Private Real Estate Credit & Income Fund (non-traded CRE-lending BDC): Blackstone Holdings IV + Blackstone Private Multi-Asset Credit & Income Fund (10%-owners) bought $2.73M [CLUSTER of 2]. Why: Affiliate seed or support capital into a young fund whose inflows fell ~72% since June; structural, not tradable. ·
news $CRBG ·
Corebridge Financial (US annuities and life insurance):
Nippon Life Insurance (10%-owner) bought $7.68M (217k sh @ $35.38). Why: A strategic ~21.6% holder is adding on the open market, a vote of confidence in the price; watch for supply when AIG’s 9.9% lock-up ends around Dec 2026. ·
news
$NXG ·
NXG NextGen Infrastructure Income Fund (closed-end infrastructure income fund): Jerry Swank (officer) bought $439k. Why: Portfolio manager buying the fund they run, possibly at a discount to NAV; low catalyst.
$SAMG ·
Silvercrest Asset Management (wealth and asset manager): Equinox Partners (10%-owner) bought $353k. Why: A value-oriented 10% holder keeps accumulating in a small-cap asset manager; watch for engagement or M&A angle.
$CRAFX ·
Cascade Real Assets Fund (real-assets interval fund): Matthew Worley (director) bought $431k. Why: A director buying an interval fund; alignment signal only, not tradable intraday.
📊 Rest: +0 other 13D filings today (all 3 shown above).
Research only — not investment advice. Thursday, October 22, 2026
📡 Alpha-Investor Signal Digest — 2026-10-22 filings
3 Schedule 13Ds scanned · 6 qualifying insider buys (no clusters)
🔍
EMERGING (high-conviction, not on roster)
$MAT ·
Mattel Inc (Barbie / Hot Wheels toy maker) — 17.68% [Med]
EdgePoint Investment Group Inc. (Toronto long-only value investor, concentrated, ~$22B AUM) · 13FScore 58/100
Why: Long-time holder (15-17%) switching from passive 13G to 13D signals intent to engage — watch for board/capital-allocation pressure or a sale push; risk is a soft toy-demand/tariff backdrop. ·
news. Book: 39 pos, top-10 67.8%
$AACG ·
ATA Creativity Global (China art-education / portfolio-training provider) — 34.51% [Med]
EVERRISE HOLDINGS LLC (holding vehicle of Chunlin Chen via Juno Cloud, AUM n/a)
Why: A control-sized block held by an individual-owned vehicle — more a control/insider position than a classic activist; possible go-private or strategic-control angle, but micro-cap liquidity and China ADR risk are high.
$BBCIW ·
Bradbury Capital Inc. (Malaysian e-voucher & digital payments, ex-SPAC) — 10.37% [Med]
YONG TECK HONG (individual investor, AUM n/a)
Why: Individual crossing 10% in a freshly de-SPACed micro-cap — likely pre-merger/insider-linked holder rather than a catalyst; treat as low-information, high-volatility.
💰
INSIDER BUYS
$DOLE ·
Dole plc (global fresh fruit & produce):
Pale Fire Capital SE (Czech activist investment group) (10%-owner) bought $8.55M. Why: Czech activist keeps adding after crossing 10% — building leverage for a value-unlock/strategic push. ·
news.
$CRBG ·
Corebridge Financial (US life insurance & annuities, ex-AIG):
Nippon Life Insurance Co (Japan’s largest life insurer, ~$600B+ assets) (10%-owner) bought $6.77M. Why: Strategic owner steadily creeping up from its 20% AIG-purchased stake — supportive bid; full-takeover optionality is the upside tail. ·
news.
5C Lending Partners Corp. (private BDC, upper-middle-market first-lien lending):
MSD Capital, L.P. (Michael Dell family office) (10%-owner) bought $9.57M. Why: Dell family office funding capital calls in a non-traded BDC (~24% owner) — not tradeable, signals continued private-credit commitment.
$RAPP ·
Rapport Therapeutics (precision neuroscience, epilepsy drug RAP-219): Steven M. Paul (director, co-founder; Karuna founder) bought $0.97M. Why: Serial biotech founder buying his own name — conviction ahead of clinical readouts; binary trial risk.
$MXF ·
Mexico Equity & Income Fund (closed-end Mexico equity fund):
Saba Capital Management (closed-end-fund discount activist, ~$5B) (10%-owner) bought $0.33M. Why: Saba routine discount-arb accumulation — catalyst is a tender/liquidity event narrowing the NAV discount.
$LEO ·
BNY Mellon Strategic Municipals (closed-end muni bond fund):
Saba Capital Management (10%-owner) bought $0.26M. Why: Same Saba discount-narrowing playbook in muni CEFs.
📊 Rest: +0 other 13D filings today.
Research only — not investment advice. Wednesday, October 21, 2026
📈 Alpha-Investor Signal Digest — 2026-10-22 (filings of 2026-10-21 · 5 13Ds, 7 unique Form 4 buys scanned)
🎯 PRIORITY (roster names)
$IOND ·
Ionic Digital Inc. (ex-Celsius miner turned AI data-center landlord) — 9.99% [High] · roster: Scott Ferguson / Sachem Head
Sachem Head Capital Management LP (concentrated activist hedge fund, ~$7.2B AUM) — filed SCHEDULE 13D · 13FScore 58/100
Why: Sachem Head capped at 9.99% and went 13D (not 13G) in a fresh July direct listing, signalling intent to push on strategy or capital allocation at a 234 MW Texas site leased to Nscale; catalyst is a strategic review or re-rating as an AI infra name, risk is bitcoin-linked volatility and a thin post-listing float ·
news. Book: 19 pos, top-10 74.5%.
🔍 EMERGING (high-conviction, not on roster)
$POLA ·
Polar Power, Inc. (DC power generators for telecom and military) — 9.99% [Med]
Mayer Christopher Jay (investor via CL Investment Group, now Co-CEO)
Why: Mayer put in capital in August and was named Co-CEO on Oct 12 to run capital markets and IR; an insider-led turnaround with a 9.99% cap, so expect financing or deal activity, with dilution as the main risk ·
news
$ICON ·
Icon Energy Corp (Greek dry-bulk shipper, 3 vessels) — 9.0% [Med]
Hampton Financial Corp (Toronto private-equity and merchant bank)
Why: Hampton bought ~10% in May calling the stock deeply below a ~$7 NAV, and has now switched from 13G to 13D, which hints it may push for value unlocking; micro-cap, illiquid and exposed to dilutive raises ·
news
$BGX ·
Blackstone Long-Short Credit Income Fund (leveraged-loan closed-end fund) — 5.87% [Med]
Saba Capital Management, L.P. (Boaz Weinstein's CEF-discount activist, ~$5B AUM) · 13FScore 85/100
Why: Saba bought steadily from Sept 8 to Oct 20 at ~$10.4-10.7 and filed a 13D, the usual opening move in its playbook of pushing for a tender or conversion to close the NAV discount; upside is capped at the discount width.
💰 INSIDER BUYS
$GXVIX ·
Global X Venture & Innovation Fund (unlisted venture interval fund): GLOBAL X MANAGEMENT COMPANY, INC. (10%-owner) bought $25.0M. Why: Sponsor seed capital into its own interval fund; no tradable read-through for stock investors.
$CRBG ·
Corebridge Financial, Inc. (US annuities and life insurer): NIPPON LIFE INSURANCE CO (10%-owner) bought $5.59M. Why: Japan's largest life insurer keeps adding to the strategic stake it bought from AIG, steady creeping-control conviction ·
news.
$BPRE ·
Bluerock Private Real Estate Fund (real-estate interval fund): KAMFAR RAMIN (director, Bluerock founder) bought $3.35M. Why: The founder buying his own fund over three days signals confidence in NAV, but it is an unlisted vehicle with limited liquidity.
$FBK ·
FB Financial Corp (Nashville-based regional bank): INGRAM ORRIN H II (director) bought $1.54M. Why: A long-time director and Ingram Industries chief putting $1.5M into the stock at ~$53 is a credible vote on regional-bank credit and earnings.
$TENX ·
TENAX THERAPEUTICS, INC. (pulmonary hypertension biotech, TNX-103): ADAR1 Capital Management, LLC (10%-owner) bought $1.46M. Why: Biotech fund ADAR1 (~14% holder) keeps averaging down at ~$1.66 after the August late-stage setback, betting on cash value or a pipeline reset; high binary risk ·
news.
$GF ·
NEW GERMANY FUND INC (German mid-cap closed-end fund): Saba Capital Management, L.P. (10%-owner) bought $907K. Why: Saba keeps building its discount campaign here.
MSD Investment Corp. (Dell family office-backed BDC, non-traded): Williams Brian S (officer) bought $311K. Why: Officer buying into a private BDC; small, little read-through.
📊 Rest: +1 other 13D filing today (SPAC-sponsor filing: Frazier Life Sciences sponsor, 20.5% of FLSC).
Research only — not investment advice. Tuesday, October 20, 2026
📈 Alpha-Investor Signal Digest — 2026-10-21 (filings of 2026-10-20 · 1 13D, 17 Form 4 buy rows scanned)
🔍 EMERGING (high-conviction, not on roster)
$STWI ·
TEG OVERSEAS, INC. (micro-cap shell company, formerly StageWise Strategies) — 31.14% [Med]
Abduvakhitova Irodakhon (individual investor, first-time filer)
Why: A 31% block taken by an individual in a tiny shell usually means a change of control ahead of a reverse merger or new business injection; speculative and illiquid, so treat it as an event watch, not a conviction long.
💰 INSIDER BUYS
$CRBG ·
Corebridge Financial, Inc. (US annuities and life insurer): NIPPON LIFE INSURANCE CO (10%-owner) bought $12.05M. Why: Japan's largest life insurer is adding to the ~21.6% strategic stake it bought from AIG in 2024, a sign of long-term conviction and possible creeping control ·
news.
$SCISX ·
MA Specialty Credit Income Fund (asset-backed private credit interval fund): MA Eagle II Holdings Fund (10%-owner) bought $2.40M. Why: Affiliated-vehicle capital going into MA Financial's US credit interval fund; looks like sponsor support, little read-through for stock investors.
$LEO ·
BNY Mellon Strategic Municipals, Inc. (muni-bond closed-end fund): Saba Capital Management, L.P. (10%-owner) bought $1.91M. Why: Saba has crossed 10% and is pushing a board nominee; the trade is a bet on narrowing the fund's discount to NAV through a tender offer or conversion ·
news.
$DSM ·
BNY Mellon Strategic Municipal Bond Fund, Inc. (muni-bond closed-end fund): Saba Capital Management, L.P. (10%-owner) bought $1.10M. Why: Same Saba discount-arbitrage playbook as LEO in the sister BNY muni fund.
$JOF ·
Japan Smaller Capitalization Fund Inc (Japan small-cap closed-end fund): Saba Capital Management, L.P. (10%-owner) bought $552K. Why: Saba is building up its stake to force action on the discount.
$ECF ·
Ellsworth Growth & Income Fund Ltd (convertibles closed-end fund): Saba Capital Management, L.P. (10%-owner) bought $386K. Why: Saba continues its CEF discount campaign.
$BOLD ·
Boundless Bio, Inc. (ecDNA-targeted oncology biotech): TANG KEVIN (10%-owner) bought $350K. Why: Tang Capital typically buys cash-rich biotechs trading near or below cash; the upside is a liquidation, reverse merger or wind-down payout.
$GF ·
New Germany Fund Inc (German mid-cap closed-end fund): Saba Capital Management, L.P. (10%-owner) bought $311K. Why: Saba is adding to another discounted CEF.
📊 Rest: +0 other 13D filings today.
Research only — not investment advice. Monday, October 19, 2026
📈 Alpha-Investor Signal Digest — filings of Oct 19, 2026
1 13D scanned · 29 qualifying Form 4 buy rows (10 unique issuers, 2 clusters)
🔍 EMERGING (high-conviction, not on roster)
$RNTZ ·
Rantizo (ag spray-drone platform; ex-SKK Holdings, ticker changed from SKK on Oct 13) — 9.02% [Med]
OLDRIDGE PHILLIP (individual holder; role not publicly identified)
Why: New 9% holder reporting right after SKK closed its ~$259M all-stock purchase of Rantizo's drone assets — most likely a share allocation from the deal rather than open-market accumulation. Reverse-merger-style structure with a thin float: expect volatility, dilution and lock-up overhangs. ·
news
💰 INSIDER BUYS
$APLD ·
Applied Digital Corp. (AI/HPC data-center developer): Jason Zhang (officer) bought $5.7M at ~$18.86 + Wes Cummins (CEO, director) bought $1.0M at ~$18.04 [CLUSTER of 2]. Why: The first open-market buys by these executives in years (both were sellers in 2025-26), coming after a ~50% drawdown from the May peak despite FQ1 revenue up 322% — a strong management conviction signal; ~$6.4B of debt is the main risk. ·
news
$CTY ·
City Therapeutics, Inc. (Phase 1 siRNA biotech, Factor XI anticoagulant): ARCH Venture Partners XII (10% owner) + Robert Nelsen (director, ARCH co-founder) bought $3.1M at the $18 IPO [CLUSTER of 2 — same ARCH group]. Why: The largest pre-IPO holder (~35%) topping up in the upsized $200M Oct 16 IPO — continuing conviction, but structural rather than a fresh open-market buy; early-stage data and lock-up expiry are the risks. ·
news
$LNBIX ·
Lincoln Bain Capital Total Credit Fund (interval private-credit fund): Lincoln Financial Investments Corp (10% owner) bought $25.0M at $10.09. Why: Sponsor seed/support capital into its own non-traded credit vehicle — structural, not a tradable signal.
$CRBG ·
Corebridge Financial, Inc. (US life insurance & annuities): Nippon Life Insurance (10% owner) bought $17.1M at ~$34.38. Why: Japan's largest life insurer, which bought ~21.6% from AIG in Dec 2024 at $31.47, is adding in the open market — strategic stake creep that supports the shares; rate and annuity-spread sensitivity is the risk.
$IAM ·
Iambic Therapeutics, Inc. (Nvidia-backed AI drug discovery, oncology): Evan Rachlin (director) bought $11.5M at the $16 IPO. Why: A large director allocation in the $150M Oct 15 IPO (priced mid-range, popped ~13-16% on debut) — a solid vote of confidence, though IPO buys are weaker signals than open-market ones; clinical-stage risk around lead IAM1363. ·
news
$BPRE ·
Bluerock Private Real Estate Fund (interval real-estate fund): Ramin Kamfar (director, Bluerock founder) bought $2.4M at ~$12.39. Why: Founder adding to his own interval fund — alignment, but low signal for stock traders.
$SNES ·
SenesTech, Inc. (rodent fertility-control products): Glenbrook Capital Management (10% owner) bought $706K at ~$0.70. Why: Large holder averaging into a sub-$1 micro-cap; dilution and listing-compliance risk dominate.
$CNXU ·
Conexeu Sciences Inc. (small-cap biotech): Lynn Sebastian Purcell (director, 10% owner) bought $500K at $3.00. Why: Round $3.00 price suggests an offering allocation rather than open-market buying — modest signal.
$EP ·
Empire Petroleum Corp (small-cap oil & gas producer): Phil Mulacek (director, 10% owner) bought $313K at ~$3.20. Why: Largest holder continuing to accumulate near lows; small size, commodity-price risk.
$ACOG ·
Alpha Cognition Inc. (commercial-stage Alzheimer's drug company): Opaleye Management (10% owner, healthcare fund) bought $309K at ~$8.23. Why: Specialist healthcare holder adding modestly to its position — steady, low-intensity support.
Research only — not investment advice. Friday, October 16, 2026
📈 Alpha-Investor Signal Digest — filings of Oct 16, 2026
4 13Ds scanned · 18 qualifying Form 4 buy rows (7 unique issuers, 1 cluster)
🔍 EMERGING (high-conviction, not on roster)
$TRXB ·
TRex Bio, Inc. (Treg immunology biotech, autoimmune & inflammation) — 19.9% [Med]
ELI LILLY & Co (big pharma strategic partner; ~$1.1B milestone deal with TRex)
Why: Lilly bought into the Oct 9 IPO ($14, low end) up to its 19.9% cap, cementing itself as top holder of a partner whose three programs it already funds — a strategic backstop and possible future M&A option. Risk: early-stage science; IPO priced at bottom of range. ·
news
$TRXB ·
TRex Bio, Inc. (Treg immunology biotech) — 7.0% [Med]
SV Biotech Crossover Opportunities Fund LP (SV Health Investors crossover healthcare fund)
Why: Pre-IPO crossover holder reporting post-IPO — continuing conviction alongside Lilly, structural rather than a new buy. Lock-up expiry is the medium-term overhang.
$AIOK ·
AI OKTO Corp. (Cyprus LPG carrier spin-off, listed Oct 9) — 74.2% [Med]
Pani Corp. (control vehicle linked to Panagiotidis/Toro group)
Why: Control-holder 13D after the spin-off listing — structural, not an activist campaign. Thin float and controlled governance; trades near 52-week lows (~$6).
$LHAI ·
Linkhome Holdings Inc. (AI real-estate tech micro-cap, Irvine CA) — 20.1% [Med]
Qin Zhen (founder, CEO & chairman)
Why: Founder-CEO 13D update on a ~$15-20M micro-cap; he has been a seller this year, so this is a holdings report, not an accumulation signal. Treat as noise.
💰 INSIDER BUYS
$BORR ·
Borr Drilling Ltd (jack-up offshore driller): Tor Olav Trøim (director) bought $2.3M + Harvey Snowling (officer) bought $1.5M [CLUSTER of 2]. Why: Founder-director keeps buying all October (~$4.60) and now an officer joins — strengthening conviction in the offshore rig upcycle; high leverage is the risk.
$PEP ·
PepsiCo, Inc. (global snacks & beverages): Robert C. Pohlad (director) bought $23.7M at ~$128. Why: A rare, very large open-market director buy in a mega-cap near multi-year lows — a strong value signal from a long-time bottler-family insider.
$PAM ·
Pampa Energía S.A. (Argentine power & gas producer): Marcos Marcelo Mindlin (chairman, 10% owner) bought $35.1M at ~$80.8/ADS. Why: Founder resumes buying (after Aug–Sep share purchases) — big bet on Argentine energy/Vaca Muerta ahead of macro catalysts; country/FX risk dominates.
$CRBG ·
Corebridge Financial, Inc. (US life & retirement insurer): Nippon Life Insurance Co (10% owner) bought $20.5M at ~$34. Why: Strategic owner keeps creeping up its stake week after week — supportive bid, possible eventual larger control.
Keenova Therapeutics plc (ex-Mallinckrodt specialty pharma, pre-NYSE listing): GoldenTree Asset Management LP (10% owner) bought $12.3M at $90. Why: Distressed-debt-turned-equity holder adding to a ~21% stake ahead of Keenova’s planned NYSE listing — a pre-IPO conviction bet.
$SAFX ·
XCF Global, Inc. (sustainable aviation fuel producer): EEME Energy SPV I, LLC (10% owner) reported $142.1M at $1.19. Why: Tied to EEME’s funding/share-cap arrangement for the New Rise Reno SAF plant — likely structural rather than a clean open-market buy; heavy dilution and resale overhang.
$SAH ·
Sonic Automotive, Inc. (US auto dealership group): Paul P. Rusnak (10% owner) bought $0.75M at ~$59.9. Why: Large holder adding modestly — mild supportive signal.
📊 Rest: +0 other 13D filings today (low conviction / small stakes / control & SPAC-sponsor filings).
Research only — not investment advice.